BULLOUS PEMPHIGOID (BP)
Clinical trials for BULLOUS PEMPHIGOID (BP) explained in plain language.
Never miss a new study
Get alerted when new BULLOUS PEMPHIGOID (BP) trials appear
Sign up with your email to follow new studies for BULLOUS PEMPHIGOID (BP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control ENROLLING_BY_INVITATIONThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Matched conditions: BULLOUS PEMPHIGOID (BP)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Scientists hunt for clues to predict blistering disease severity
Knowledge-focused OngoingThis study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to m…
Matched conditions: BULLOUS PEMPHIGOID (BP)
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC